Regulatory Strategy for Drug and Device Development
Regulatory Strategy for Drug and Device Development. Why it must start on Day One. In the fast-paced world of life sciences innovation, the drive to “get moving” can be irresistible. Teams dive into development, eager to demonstrate progress.Yet the companies that succeed long-term are those that pause first to plan, align, and build a regulatory…
TGA Provisional Registration Pathway Australia
TGA Provisional Registration: Accelerating Patient Access to Medicines in Australia In Australia, the Therapeutic Goods Administration (TGA) offers a provisional registration pathway for prescription medicines. This pathway enables earlier patient access to certain promising new medicines, based on preliminary clinical data. In other markets, comparable processes may be known as conditional approval, or similar. Eligible…
Australia and the ACCESS Consortium: Navigating Regulatory Collaboration
The Access Consortium is a coalition of like-minded regulatory authorities working together to promote greater regulatory collaboration and alignment of regulatory requirements. Learn how the ACCESS Consortium can streamline medicine approvals in Australia and partner countries, accelerating access to new therapies. Australia as an Early Entry Market for Medicines Australia is an increasingly attractive early…
Disclaimer:
The information provided is intended for general informational purposes only and does not constitute legal, professional, or any other type of advice. While every effort has been made to ensure the accuracy and reliability of the information, the authors make no representations or warranties, express or implied, regarding the completeness, suitability, or applicability of the content to specific products or situations.